# US 2025/0066415 A1 · Systems for extracting proteins from a blood-based material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0066415 A1
- Document ID: US20250066415A1
- Status: Published application
- Kind: A1
- Application number: 18/944,442
- Filed: 2024-11-12
- Published: 2025-02-27
- Earliest claimed: 2016-02-03
- Inventors: Eugene Zurlo; Dennis Curtin; David Peter Nowotnik; Charles Heldebrant
- Web page: https://patentgrep.com/patent/US20250066415A1

## CPC

- C07K 1/36: by a combination of two or more processes of different types
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/363: {Fibrinogen}
- A61K 38/37: Factors VIII
- A61K 38/38: Albumins
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- B01D 15/361: {Ion-exchange}
- B01D 15/3814: {of the substrate or cofactor-enzyme type}
- B01D 61/027: {Nanofiltration}
- B01D 61/145: {Ultrafiltration}
- C07K 1/16: by chromatography
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 1/30: by precipitation
- C07K 1/34: by filtration, ultrafiltration or reverse osmosis
- C07K 14/81: Protease inhibitors
- C07K 16/06: from serum
- B01D 2315/16: Diafiltration
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

Methods of producing multiple protein products from blood-based materials including alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins are described herein. The inventive methods include steps of: salt fractionation, chromatography, ultrafiltration, diafiltration, solvent-detergent treatment, and sterile filtration. Advantageously, the inventive methods are simple and produce alpha-1-proteinase inhibitor, gamma globulin, albumin, and other proteins in high yields. The sequence of process steps can be selected to obtain multiple products from various in-process materials, such as supernatants, pastes, chromatography flow-though, and chromatography washes.

## Claims

### Claim 1

A system for isolating immunoglobulin G (IgG) from a blood product, comprising:
a source of a starting material comprising a blood product;
a first fractionation module fluidically coupled to the source of starting material and comprising a first precipitating salt, a first output, and a second output, wherein the first fractionation module is configured to direct a first supernatant derived from the blood product by application of the first precipitating salt to the first output and a first precipitate derived from the blood product by application of the first precipitating salt to the second output;
a second fractionation module fluidically coupled to the first output and comprising a second precipitating salt, a third output, and a fourth output, wherein the second fractionation module is configured to direct a second supernatant derived from the first supernatant by application of the second precipitating salt to the third output and a second precipitate derived from the first supernatant by application of the second precipitating salt to the fourth output;
a first chromatography module arranged to receive a dissolved second precipitate and comprising an anion exchange resin, wherein the first chromatography module is configured to direct a first flow-through fraction derived from the dissolved second precipitate to a fifth output and a first eluted fraction derived from the dissolved second precipitate to a sixth output; and
a second chromatography module that is in fluidic communication with the fifth output and comprising an anion exchange media, wherein the second chromatography module is configured to direct a second flow-through fraction derived from the first flow-through fraction and comprising IgG to a seventh output and a second eluted fraction derived from the first flow-through fraction to an eighth output.

### Claim 2 (depends on 1)

The system of claim 1, further comprising a viral inactivation or viral removal module fluidically coupled to the first chromatography module.

### Claim 3 (depends on 1)

The system of claim 1, further comprising a third chromatography module fluidically coupled to the seventh output, wherein the third chromatography module is configured to direct a third flow-through fraction derived from the second flow-through fraction to a ninth output and a third eluate derived from the second flow-through fraction and comprising IgG to a tenth output.

### Claim 4 (depends on 3)

The system of claim 3, wherein the third chromatography module comprises a cation exchange media.

### Claim 5 (depends on 3)

The system of claim 3, wherein the third chromatography module comprises an affinity media.

### Claim 6 (depends on 1)

The system of claim 1, further comprising a diafiltration or dialysis module fluidically coupled to the first chromatography module.
